Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
US Army
Boehringer Ingelheim
Daiichi Sankyo
Chubb
Johnson and Johnson
McKesson
Cerilliant
Novartis
US Department of Justice

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,073,933

« Back to Dashboard

Summary for Patent: 9,073,933
Title:Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
Abstract: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.
Inventor(s): Chapman; Robert (North Kingstown, RI), Rider; Lonn S. (Foster, RI), Hong; Qi (Sharon, MA), Kyle; Donald (Newtown, PA), Kupper; Robert (Coventry, RI)
Assignee: Purdue Pharma L.P. (Stamford, CT) The P.F. Laboratories, Inc. (Totowa, NJ) Purdue Pharmaceuticals L.P. (Wilson, NC) Rhodes Technologies (Coventry, RI)
Application Number:13/366,755
Patent Claim Types:
see list of patent claims
Composition; Process;

Drugs Protected by US Patent 9,073,933

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-001 Apr 5, 2010 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-002 Apr 5, 2010 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-003 Apr 5, 2010 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-004 Apr 5, 2010 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-005 Apr 5, 2010 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-006 Apr 5, 2010 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-007 Apr 5, 2010 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Purdue Pharma Lp TARGINIQ naloxone hydrochloride; oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 205777-001 Jul 23, 2014 DISCN Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Purdue Pharma Lp TARGINIQ naloxone hydrochloride; oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 205777-002 Jul 23, 2014 DISCN Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Purdue Pharma Lp TARGINIQ naloxone hydrochloride; oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 205777-003 Jul 23, 2014 DISCN Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,073,933

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,683,072 Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone ➤ Subscribe
7,129,248 Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone ➤ Subscribe
9,777,011 Process for preparing oxycodone compositions ➤ Subscribe
7,674,798 Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone ➤ Subscribe
8,822,687 8a,14-dihydroxy-7,8-dihydrocodeinone ➤ Subscribe
7,674,800 Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone ➤ Subscribe
7,674,799 Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone ➤ Subscribe
9,522,919 Oxycodone compositions ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,073,933

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Ukraine 86411 ➤ Subscribe
Taiwan 201509943 ➤ Subscribe
Taiwan I483944 ➤ Subscribe
Taiwan 201231469 ➤ Subscribe
Taiwan I365880 ➤ Subscribe
Taiwan 200540177 ➤ Subscribe
Tunisia SN06312 ➤ Subscribe
Slovenia 2426132 ➤ Subscribe
Slovenia 2319846 ➤ Subscribe
Slovenia 2305683 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Chubb
Fuji
Chinese Patent Office
Teva
Julphar
Fish and Richardson
Deloitte
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot